ADVM Adverum Biotechnologies, Inc.

Nasdaq adverum.com


$ 4.38 $ -0.07 (-1.53 %)    

Friday, 17-Oct-2025 10:55:12 EDT
QQQ $ 599.73 $ 2.26 (0.38 %)
DIA $ 460.03 $ 0.63 (0.14 %)
SPY $ 660.57 $ 1.12 (0.17 %)
TLT $ 91.04 $ -0.20 (-0.22 %)
GLD $ 391.87 $ -5.32 (-1.34 %)
$ 4.56
$ 4.56
$ 4.35 x 34
$ 4.42 x 4
$ 4.50 - $ 4.56
$ 1.78 - $ 8.56
174,454
na
95.69M
$ 0.99
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 04-15-2025 12-31-2024 10-K
4 11-04-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-18-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-30-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-29-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-01-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-28-2020 03-31-2020 10-Q
23 03-12-2020 12-31-2019 10-K
24 11-07-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-08-2019 03-31-2019 10-Q
27 03-06-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-08-2018 06-30-2018 10-Q
30 05-09-2018 03-31-2018 10-Q
31 03-06-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 03-09-2017 12-31-2016 10-K
36 11-08-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-06-2016 03-31-2016 10-Q
39 03-04-2016 12-31-2015 10-K
40 11-09-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-adverum-biotechnologies-maintains-30-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and maintains $...

 chardan-capital-maintains-buy-on-adverum-biotechnologies-maintains-33-price-target

Chardan Capital analyst Daniil Gataulin maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and maintains $33 price t...

 adverum-biotechnologies-q2-eps-234-misses-221-estimate

Adverum Biotechnologies (NASDAQ:ADVM) reported quarterly losses of $(2.34) per share which missed the analyst consensus estimat...

 mizuho-maintains-outperform-on-adverum-biotechnologies-lowers-price-target-to-12

Mizuho analyst Graig Suvannavejh maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Outperform and lowers the price targ...

 rbc-capital-maintains-sector-perform-on-adverum-biotechnologies-lowers-price-target-to-4

RBC Capital analyst Luca Issi maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Sector Perform and lowers the price tar...

 chardan-capital-maintains-buy-on-adverum-biotechnologies-maintains-33-price-target

Chardan Capital analyst Daniil Gataulin maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and maintains $33 price t...

 hc-wainwright--co-reiterates-buy-on-adverum-biotechnologies-maintains-30-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and maintains $...

 adverum-biotechnologies-q1-eps-225-misses-194-estimate

Adverum Biotechnologies (NASDAQ:ADVM) reported quarterly losses of $(2.25) per share which missed the analyst consensus estimat...

 chardan-capital-maintains-buy-on-adverum-biotechnologies-lowers-price-target-to-33

Chardan Capital analyst Daniil Gataulin maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and lowers the price targ...

 rbc-capital-maintains-sector-perform-on-adverum-biotechnologies-lowers-price-target-to-5

RBC Capital analyst Luca Issi maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Sector Perform and lowers the price tar...

 hc-wainwright--co-reiterates-buy-on-adverum-biotechnologies-maintains-30-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and maintains $...

 adverum-biotechnologies-q4-eps-196-misses-138-estimate

Adverum Biotechnologies (NASDAQ:ADVM) reported quarterly losses of $(1.96) per share which missed the analyst consensus estimat...

 adverum-biotechnologies-initiates-artemis-phase-3-study-evaluating-ixo-vec-for-wet-amd

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequen...

 hc-wainwright--co-reiterates-buy-on-adverum-biotechnologies-maintains-30-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and maintains $...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION